ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO LTD has a total of 11 patent applications. It decreased the IP activity by 83.0%. Its first patent ever was published in 2016. It filed its patents most often in United States, Canada and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are VIVOLUX AB, FEDORA PHARMACEUTICALS INC and LOHOCLA RES CORPORATION.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 3 | |
#2 | Canada | 2 | |
#3 | EPO (European Patent Office) | 2 | |
#4 | China | 1 | |
#5 | Republic of Korea | 1 | |
#6 | Mexico | 1 | |
#7 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Heterocyclic compounds | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Lu Zhijian | 10 |
#2 | Liao Xibin | 10 |
#3 | Li Jia | 10 |
#4 | Zhou Yubo | 10 |
#5 | Gao Anhui | 10 |
#6 | Yubo Zhou | 1 |
#7 | Jia Li | 1 |
#8 | Zhijian Lu | 1 |
#9 | Anhui Gao | 1 |
#10 | Xibin Liao | 1 |
Publication | Filing date | Title |
---|---|---|
US2019276453A1 | Bruton's tyrosine kinase inhibitors | |
EP3405192A1 | Bruton's tyrosine kinase inhibitors | |
EP3414234A1 | Bruton's tyrosine kinase inhibitors |